Bright Peak Therapeutics has filed a notice of an exempt offering of securities to raise $89,999,991.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Bright Peak Therapeutics is raising up to $89,999,991.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Fredrik Wiklund played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Bright Peak Therapeutics
Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary Bright Peak Immunocytokines, and to other cytokines as duokines. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its off-the-shelf feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peaks cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peaks team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.
To learn more about Bright Peak Therapeutics, visit http://brightpeaktx.com/
Company Linkedin Page: https://www.linkedin.com/company/bright-peak-therapeutics/
Contact:
Fredrik Wiklund, Chief Executive Officer
626-298-0609
https://www.linkedin.com/in/fred-wiklund-43361551/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.